HC Wainwright Has Pessimistic View of HRTX FY2026 Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Stock analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of Heron Therapeutics in a report issued on Wednesday, June 3rd. HC Wainwright analyst B. Folkes now forecasts that the biotechnology company will earn ($0.09) per share for the year, down from their prior forecast of ($0.08). HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for Heron Therapeutics’ FY2027 earnings at $0.00 EPS, FY2028 earnings at $0.12 EPS, FY2029 earnings at $0.22 EPS and FY2030 earnings at $0.32 EPS.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Monday, May 11th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%.The firm had revenue of $34.71 million during the quarter, compared to analyst estimates of $36.72 million.

A number of other equities research analysts have also commented on the company. Needham & Company LLC lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Research lowered Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, April 27th. Wall Street Zen lowered Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Heron Therapeutics presently has an average rating of “Hold” and an average target price of $2.50.

Heron Therapeutics Price Performance

Shares of HRTX opened at $0.48 on Friday. Heron Therapeutics has a 12-month low of $0.43 and a 12-month high of $2.30. The business has a 50-day simple moving average of $0.92 and a two-hundred day simple moving average of $1.11. The company has a quick ratio of 1.51, a current ratio of 2.53 and a debt-to-equity ratio of 17.51. The stock has a market cap of $91.52 million, a PE ratio of -2.69 and a beta of 1.58.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Rubric Capital Management LP lifted its stake in shares of Heron Therapeutics by 3.3% in the 4th quarter. Rubric Capital Management LP now owns 30,046,828 shares of the biotechnology company’s stock valued at $39,061,000 after purchasing an additional 946,100 shares during the period. Clearline Capital LP lifted its stake in shares of Heron Therapeutics by 26.0% in the 4th quarter. Clearline Capital LP now owns 12,235,239 shares of the biotechnology company’s stock valued at $15,906,000 after purchasing an additional 2,522,712 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in shares of Heron Therapeutics by 9.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 11,185,325 shares of the biotechnology company’s stock valued at $14,541,000 after purchasing an additional 946,100 shares during the period. Orbimed Advisors LLC acquired a new position in shares of Heron Therapeutics in the 1st quarter valued at about $7,855,000. Finally, Velan Capital Investment Management LP lifted its stake in shares of Heron Therapeutics by 25.3% in the 3rd quarter. Velan Capital Investment Management LP now owns 8,753,290 shares of the biotechnology company’s stock valued at $11,029,000 after purchasing an additional 1,766,546 shares during the period. 80.01% of the stock is owned by institutional investors and hedge funds.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.